Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Biomed Biotechnol ; 2010: 724914, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-20467471

RESUMO

Ischemia/reperfusion (IR) injury can induce skeletal muscle fibre death and subsequent regeneration. By 14 days, absolute and specific maximal forces and fatigue resistance in ischemic/reperfused soleus muscles were still reduced (-89%, -81%, and -75%, resp.) as compared to control muscles (P < .05). The decrease of these parameters in ischemic/reperfused muscle was much greater than that of myotoxic injured muscles (-12%, -11%, and -19%; P < .05). In addition, at 14 days ischemic/reperfused muscle structure was still abnormal, showing small muscle fibres expressing neonatal myosin heavy chain and large necrotic muscle fibres that were not observed in myotoxin treated muscles. By 56 days, in contrast to myotoxin treated muscles, specific maximal force and muscle weight of the ischemic/reperfused muscles did not fully recover (P < .05). This differential recovery between ischemic/reperfused and myotoxin treated muscles was not related to the differences in the initial cell death, loss of satellite cells after injury, expression of growth factors (IGF1, IGF2..), or capillary density in regenerating muscles. In conclusion, our results demonstrate that IR injury in mice induces long term detrimental effects in skeletal muscles and that the recovery following IR injury was delayed for yet unknown reasons as compared to myotoxic injury.


Assuntos
Músculo Esquelético , Regeneração/fisiologia , Traumatismo por Reperfusão , Análise de Variância , Animais , Fenômenos Biomecânicos , Morte Celular , Linhagem Celular , Citocinas/metabolismo , Membro Posterior/metabolismo , Membro Posterior/patologia , Membro Posterior/fisiopatologia , Histocitoquímica , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Contração Muscular , Músculo Esquelético/lesões , Músculo Esquelético/metabolismo , Músculo Esquelético/patologia , Músculo Esquelético/fisiopatologia , Cadeias Pesadas de Miosina/metabolismo , Traumatismo por Reperfusão/metabolismo , Traumatismo por Reperfusão/fisiopatologia
2.
Metab Brain Dis ; 24(2): 321-35, 2009 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-19319673

RESUMO

The basal ganglia, which are interconnected in the striato-nigral dopaminergic network, are affected in several childhood diseases including Leigh syndrome (LS). LS is the most common mitochondrial disorder affecting children and usually arise from inhibition of the respiratory chain. This vulnerability is attributed to a particular susceptibility to energetic stress, with mitochondrial inhibition as a common pathogenic pathway. In this study we developed a LS model for neuroprotection trials in mice by using the complex I inhibitor MPTP. We first verified that MPTP significantly inhibits the mitochondrial complex I in the brain (p = 0.018). This model also reproduced the biochemical and pathological features of LS: MPTP increased plasmatic lactate levels (p = 0.023) and triggered basal ganglia degeneration, as evaluated through dopamine transporter (DAT) autoradiography, tyrosine hydroxylase (TH) immunohistochemistry, and dopamine dosage. Striatal DAT levels were markedly decreased after MPTP treatment (p = 0.003). TH immunoreactivity was reduced in the striatum and substantia nigra (p = 0.005), and striatal dopamine was significantly reduced (p < 0.01). Taken together, these results confirm that acute MPTP intoxication in young mice provides a reproducible pharmacological paradigm of LS, thus opening new avenues for neuroprotection research.


Assuntos
Modelos Animais de Doenças , Complexo I de Transporte de Elétrons/metabolismo , Doença de Leigh/enzimologia , Intoxicação por MPTP/enzimologia , Doenças Mitocondriais/induzido quimicamente , 1-Metil-4-Fenil-1,2,3,6-Tetra-Hidropiridina , Animais , Gânglios da Base/enzimologia , Gânglios da Base/patologia , Doenças dos Gânglios da Base/induzido quimicamente , Doenças dos Gânglios da Base/enzimologia , Doenças dos Gânglios da Base/patologia , Dopamina/metabolismo , Complexo I de Transporte de Elétrons/efeitos dos fármacos , Metabolismo Energético/efeitos dos fármacos , Inibidores Enzimáticos , Ácido Láctico/sangue , Doença de Leigh/induzido quimicamente , Doença de Leigh/patologia , Intoxicação por MPTP/patologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Doenças Mitocondriais/enzimologia , Doenças Mitocondriais/patologia , Neostriado/efeitos dos fármacos , Neostriado/metabolismo , Neostriado/patologia , Degeneração Neural/induzido quimicamente , Degeneração Neural/enzimologia , Degeneração Neural/patologia
3.
Neuroscience ; 125(1): 163-70, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-15051155

RESUMO

Methylphenidate (MPH), a dopamine reuptake inhibitor, is used increasingly to treat attention deficit and hyperactivity disorders in children. Given that dopaminergic mechanisms, contribute to the structural and functional maturation of brain circuitry, consideration of the potential influence of MPH in disrupting such processes seems warranted. Following a similar logic regarding the relevance of glutamate neurotransmission in mediating aspects of brain maturation, we and others have previously utilized in vivo and in vitro studies of the developing rodent brain to establish that MK-801, an N-methyl-d-aspartate (NMDA) receptor antagonist has both neuroprotective and pro-apoptotic actions. In this study we used a neonatal murine model of excitotoxin-induced cortical injury to compare such actions between MPH and MK-801, and found that MPH shared some biological properties with MK-801. Specifically, both drugs were neuroprotective against excitotoxic challenge resulting in neonatal brain lesions and in vitro neuronal death, but both drugs also exacerbated programmed neural cell death. However, this profile of action was not shared by the dopamine reuptake blocker GBR-12783, a molecule which like MPH binds to and blocks the dopamine transporter, but which is structurally dissimilar to MPH, suggesting that inhibition of dopamine reuptake alone cannot explain the results from our MPH studies. The implications of our findings are that when studied in our developmental mouse model both drugs demonstrate similar capacities to be either neuroprotective or pro-apoptotic, depending on the specific biologic setting in which they act. Additional studies to identify some potential positive as well as negative consequences of exposure to these drugs during brain development in clinical settings are warranted.


Assuntos
Encéfalo/efeitos dos fármacos , Maleato de Dizocilpina/farmacologia , Metilfenidato/farmacologia , Neurônios/efeitos dos fármacos , Fármacos Neuroprotetores/farmacologia , Animais , Animais Recém-Nascidos , Apoptose/efeitos dos fármacos , Encéfalo/embriologia , Lesões Encefálicas/induzido quimicamente , Inibidores da Captação de Dopamina/farmacologia , Ácido Ibotênico/toxicidade , Marcação In Situ das Extremidades Cortadas , Camundongos , Neurônios/patologia , Piperazinas/farmacologia , Receptores de N-Metil-D-Aspartato/antagonistas & inibidores
4.
Neuroscience ; 121(2): 287-96, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-14521988

RESUMO

The death of dopaminergic neurons induced by systemic administration of mitochondrial respiratory chain complex I inhibitors such as 1-methyl-4-phenylpyridinium (MPP(+); given as the prodrug 1-methyl-1,2,3,6-tetrahydropyridine) or the pesticide rotenone have raised the question as to whether this family of compounds are the cause of some forms of Parkinsonism. We have examined the neurotoxic potential of another complex I inhibitor, annonacin, the major acetogenin of Annona muricata (soursop), a tropical plant suspected to be the cause of an atypical form of Parkinson disease in the French West Indies (Guadeloupe). When added to mesencephalic cultures for 24 h, annonacin was much more potent than MPP(+) (effective concentration [EC(50)]=0.018 versus 1.9 microM) and as effective as rotenone (EC(50)=0.034 microM) in killing dopaminergic neurons. The uptake of [(3)H]-dopamine used as an index of dopaminergic cell function was similarly reduced. Toxic effects were seen at lower concentrations when the incubation time was extended by several days whereas withdrawal of the toxin after a short-term exposure (<6 h) arrested cell demise. Unlike MPP(+) but similar to rotenone, the acetogenin also reduced the survival of non-dopaminergic neurons. Neuronal cell death was not excitotoxic and occurred independently of free radical production. Raising the concentrations of either glucose or mannose in the presence of annonacin restored to a large extent intracellular ATP synthesis and prevented neuronal cell demise. Deoxyglucose reversed the effects of both glucose and mannose. Other hexoses such as galactose and fructose were not protective. Attempts to restore oxidative phosphorylation with lactate or pyruvate failed to provide protection to dopaminergic neurons whereas idoacetate, an inhibitor of glycolysis, inhibited the survival promoting effects of glucose and mannose indicating that these two hexoses acted independently of mitochondria by stimulating glycolysis. In conclusion, our study demonstrates that annonacin promotes dopaminergic neuronal death by impairment of energy production. It also underlines the need to address its possible role in the etiology of some atypical forms of Parkinsonism in Guadeloupe.


Assuntos
Dopamina/metabolismo , Metabolismo Energético/efeitos dos fármacos , Furanos/toxicidade , Lactonas/toxicidade , Mesencéfalo/efeitos dos fármacos , Mitocôndrias/efeitos dos fármacos , Neurônios/efeitos dos fármacos , Neurotoxinas/toxicidade , 1-Metil-4-fenilpiridínio/toxicidade , Acetilcisteína/farmacologia , Trifosfato de Adenosina/análise , Animais , Antioxidantes/farmacologia , Benzodiazepinas/farmacologia , Sobrevivência Celular , Células Cultivadas , Cromanos/farmacologia , Desoxiglucose/metabolismo , Maleato de Dizocilpina/farmacologia , Relação Dose-Resposta a Droga , Interações Medicamentosas , Embrião de Mamíferos , Metabolismo Energético/fisiologia , Antagonistas de Aminoácidos Excitatórios , Feminino , Furanos/química , Glucose/farmacologia , Herbicidas/toxicidade , Hexoses/farmacologia , Inseticidas/toxicidade , Espaço Intracelular/metabolismo , Lactonas/química , Masculino , Manose/farmacologia , Mesencéfalo/citologia , Mesencéfalo/fisiologia , Proteínas Associadas aos Microtúbulos/metabolismo , Neurônios/fisiologia , Neurotoxinas/química , Extratos Vegetais/química , Extratos Vegetais/toxicidade , Gravidez , Ratos , Ratos Wistar , Espécies Reativas de Oxigênio , Rotenona/toxicidade , Trítio/metabolismo , Tirosina 3-Mono-Oxigenase/metabolismo
5.
Mitochondrion ; 9(5): 331-9, 2009 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-19439198

RESUMO

Diversity of respiratory chain spectrophotometric assays may lead to difficult comparison of results between centers. The French network of mitochondrial diseases diagnostic centers undertook comparison of the results obtained with different protocols in the French diagnostic centers. The diversity of protocols was shown to have striking consequences, which prompted the network to undertake standardization and optimization of the protocols with respect to clinical diagnosis, i.e. high velocity while maintaining linear kinetics relative to time and enzyme concentration. Assays were set up on animal tissues and verified on control human muscle and fibroblasts. Influence of homogenization buffer and narrow range of optimal concentration of phosphate, substrate and tissue were shown. Experimental data and proposed protocols have been posted on a free access website. Their subsequent use in several diagnostic centers has improved consistency for all assays.


Assuntos
Transporte de Elétrons/fisiologia , Doenças Mitocondriais/diagnóstico , Espectrofotometria/métodos , Espectrofotometria/normas , França , Humanos , Internet , Reprodutibilidade dos Testes
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA